|Systematic (IUPAC) name|
|Molar mass||447.336 g/mol|
Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|